WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
These authors contributed equally to this work.
Euro Surveill. 2017 Dec;22(50). doi: 10.2807/1560-7917.ES.2017.22.50.16-00824.
Hand, foot and mouth disease (HFMD) is usually caused by several serotypes from human enterovirus A species, including enterovirus 71 (EV-A71) and coxsackievirus A16 (CV-A16). Two inactivated monovalent EV-A71 vaccines have been recently licensed in China and monovalent CV-A16 vaccine and bivalent EV-A71 and CV-A16 vaccine are under development.
Using notifications from the national surveillance system, we describe the epidemiology and dynamics of HFMD in the country, before the introduction of EV-A71 vaccination, from 2008 through 2015.
Laboratory-identified serotype categories, i.e. CV-A16, EV-A71 and other enteroviruses, circulated annually. EV-A71 remained the most virulent serotype and was the major serotype for fatal cases (range: 88.5-95.4%) and severe cases (range: 50.7-82.3%) across years. Except for 2013 and 2015, when other enteroviruses were more frequently found in mild HFMD (48.8% and 52.5%), EV-A71 was more frequently detected from mild cases in the rest of the years covered by the study (range: 39.4-52.6%). The incidence rates and severity risks of HFMD associated with all serotype categories were the highest for children aged 1 year and younger, and decreased with increasing age.
DISCUSSION/CONCLUSION: This study provides baseline epidemiology for evaluation of vaccine impact and potential serotype replacement.
手足口病(HFMD)通常由肠道病毒 A 种的几种血清型引起,包括肠道病毒 71 型(EV-A71)和柯萨奇病毒 A16 型(CV-A16)。两种已获批的灭活单价 EV-A71 疫苗已在中国上市,单价 CV-A16 疫苗和二价 EV-A71 和 CV-A16 疫苗正在研发中。
利用全国监测系统的报告,我们描述了在引入 EV-A71 疫苗之前,2008 年至 2015 年中国 HFMD 的流行病学和动态。
实验室确定的血清型类别,即 CV-A16、EV-A71 和其他肠道病毒,每年都在循环。EV-A71 仍然是最具毒力的血清型,也是导致死亡病例(范围:88.5-95.4%)和重症病例(范围:50.7-82.3%)的主要血清型。除了 2013 年和 2015 年,其他肠道病毒在轻症 HFMD 中更为常见(48.8%和 52.5%)外,在研究涵盖的其余年份中,轻症病例中更常发现 EV-A71(范围:39.4-52.6%)。与所有血清型类别相关的 HFMD 的发病率和严重风险在 1 岁及以下儿童中最高,并随年龄增长而降低。
讨论/结论:本研究为评估疫苗效果和潜在血清型替代提供了基线流行病学数据。